AIIMS panel gives nod for human clinical trials of indigenous vaccine candidate COVAXIN

The AIIMS Ethics Committee has given its nod for a human clinical trial of the indigenously developed COVID-19 vaccine candidate COVAXIN. AIIMS is likely to begin the exercise by enrolling healthy volunteers from Monday.

AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research for conducting phase I and II human trials of COVAXIN. In phase I, the vaccine would be tested on 375 volunteers and the maximum of 100 of them would be from AIIMS.

Healthy volunteers having no comorbid conditions and without a history of COVID-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomised, double-blind, placebo-controlled clinical trial.